Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 581348, 9 pages
http://dx.doi.org/10.1155/2008/581348
Research Article

Improved Insulin Resistance and Lipid Metabolism by Cinnamon Extract through Activation of Peroxisome Proliferator-Activated Receptors

Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Graduate School of CAS, Chinese Academy of Sciences, 319 Yue Yang Road, Shanghai 200031, China

Received 10 September 2008; Accepted 2 November 2008

Academic Editor: N. Wang

Copyright © 2008 Xiaoyan Sheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. A. DeFronzo and E. Ferrannini, “Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease,” Diabetes Care, vol. 14, no. 3, pp. 173–194, 1991. View at Google Scholar
  2. B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at Google Scholar
  3. G. Steiner, A. Hamsten, J. Hosking et al., “Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study,” The Lancet, vol. 357, no. 9260, pp. 905–910, 2001. View at Publisher · View at Google Scholar
  4. J. M. Olefsky, “Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists,” The Journal of Clinical Investigation, vol. 106, no. 4, pp. 467–472, 2000. View at Publisher · View at Google Scholar
  5. J. I. Cleeman, “Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” The Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001. View at Google Scholar
  6. S. Kumar, A. J. M. Boulton, H. Beck-Nielsen et al., “Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients,” Diabetologia, vol. 39, no. 6, pp. 701–709, 1996. View at Google Scholar
  7. A. B. Mayerson, R. S. Hundal, S. Dufour et al., “The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes,” Diabetes, vol. 51, no. 3, pp. 797–802, 2002. View at Google Scholar
  8. Y. Miyazaki, A. Mahankali, M. Matsuda et al., “Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone,” Diabetes Care, vol. 24, no. 4, pp. 710–719, 2001. View at Google Scholar
  9. S. Chitturi and J. George, “Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs,” Seminars in Liver Disease, vol. 22, no. 2, pp. 169–183, 2002. View at Publisher · View at Google Scholar
  10. M. S. Rendell and W. R. Kirchain, “Pharmacotherapy of type 2 diabetes mellitus,” The Annals of Pharmacotherapy, vol. 34, no. 7, pp. 878–895, 2000. View at Publisher · View at Google Scholar
  11. A. Khan, M. Safdar, M. M. A. Khan, K. N. Khattak, and R. A. Anderson, “Cinnamon improves glucose and lipids of people with type 2 diabetes,” Diabetes Care, vol. 26, no. 12, pp. 3215–3218, 2003. View at Publisher · View at Google Scholar
  12. S. H. Kim, S. H. Hyun, and S. Y. Choung, “Anti-diabetic effect of cinnamon extract on blood glucose in db/db mice,” Journal of Ethnopharmacology, vol. 104, no. 1-2, pp. 119–123, 2006. View at Publisher · View at Google Scholar
  13. N. Talpur, B. Echard, C. Ingram, D. Bagchi, and H. G. Preuss, “Effects of a novel formulation of essential oils on glucose-insulin metabolism in diabetic and hypertensive rats: a pilot study,” Diabetes, Obesity and Metabolism, vol. 7, no. 2, pp. 193–199, 2005. View at Publisher · View at Google Scholar
  14. B. Roffey, A. Atwal, and S. Kubow, “Cinnamon water extracts increase glucose uptake but inhibit adiponectin secretion in 3T3-L1 adipose cells,” Molecular Nutrition & Food Research, vol. 50, no. 8, pp. 739–745, 2006. View at Publisher · View at Google Scholar
  15. R. A. Anderson, C. L. Broadhurst, M. M. Polansky et al., “Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity,” Journal of Agricultural and Food Chemistry, vol. 52, no. 1, pp. 65–70, 2004. View at Publisher · View at Google Scholar
  16. C. Huang, Y. Zhang, Z. Gong et al., “Berberine inhibits 3T3-L1 adipocyte differentiation through the PPAR? pathway,” Biochemical and Biophysical Research Communications, vol. 348, no. 2, pp. 571–578, 2006. View at Publisher · View at Google Scholar
  17. B. Ahrén, E. Simonsson, A. J. W. Scheurink, H. Mulder, U. Myrsén, and F. Sundler, “Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet—induced insulin resistance in C57BL/6J mice,” Metabolism, vol. 46, no. 1, pp. 97–106, 1997. View at Publisher · View at Google Scholar
  18. M. S. Winzell and B. Ahrén, “The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes,” Diabetes, vol. 53, supplement 3, pp. S215–S219, 2004. View at Publisher · View at Google Scholar
  19. S. Kashyap, R. Belfort, A. Gastaldelli et al., “A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes,” Diabetes, vol. 52, no. 10, pp. 2461–2474, 2003. View at Publisher · View at Google Scholar
  20. G. Boden, “Free fatty acids, insulin resistance, and type 2 diabetes mellitus,” Proceedings of the Association of American Physicians, vol. 111, no. 3, pp. 241–248, 1999. View at Publisher · View at Google Scholar
  21. J. Betteridge, “Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus,” The American Journal of Medicine, vol. 118, supplement 12, pp. 10S–15S, 2005. View at Publisher · View at Google Scholar
  22. R. Collins, J. Armitage, S. Parish, P. Sleight, and R. Peto, “MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial,” The Lancet, vol. 360, no. 9326, pp. 7–22, 2002. View at Publisher · View at Google Scholar
  23. J. R. Downs, M. Clearfield, S. Weis et al., “Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS,” The Journal of the American Medical Association, vol. 279, no. 20, pp. 1615–1622, 1998. View at Publisher · View at Google Scholar
  24. E. L. Renner and A. Dällenbach, “Increased liver enzymes: what should be done?” Therapeutische Umschau, vol. 49, no. 5, pp. 281–286, 1992 (German). View at Google Scholar
  25. B. J. O'Connor, B. Kathamna, and A. S. Tavill, “Nonalcoholic fatty liver (NASH syndrome),” The Gastroenterologist, vol. 5, no. 4, pp. 316–329, 1997. View at Google Scholar
  26. W. L. Baker, G. Gutierrez-Williams, C. M. White, J. Kluger, and C. I. Coleman, “Effect of cinnamon on glucose control and lipid parameters,” Diabetes Care, vol. 31, no. 1, pp. 41–43, 2008. View at Publisher · View at Google Scholar
  27. B. Mang, M. Wolters, B. Schmitt et al., “Effects of a cinnamon extract on plasma glucose, HbA1c, and serum lipids in diabetes mellitus type 2,” European Journal of Clinical Investigation, vol. 36, no. 5, pp. 340–344, 2006. View at Publisher · View at Google Scholar